Squarepoint
MGX icon

Squarepoint’s Metagenomi Therapeutics MGX Stock Holding History

Squarepoint’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,594
Closed -$17.2K – 5105
2025
Q4 		$17.2K Buy
+10,594
New +$22.9K ﹤0.01% 4174
2025
Q3 		– Sell
-38,126
Closed -$56.4K – 5110
2025
Q2 		$56.4K Buy
+38,126
New +$59.7K ﹤0.01% 4288
2024
Q4 		– Sell
-11,526
Closed -$25K – 5577
2024
Q3 		$25K Buy
11,526
+1,324
+13% +$4.59K ﹤0.01% 4011
2024
Q2 		$41.6K Sell
10,202
-16,286
-61% -$112K ﹤0.01% 3925
2024
Q1 		$279K Buy
+26,488
New +$304K ﹤0.01% 3440

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint's MGX Position: Q1 2026 in Review

Squarepoint sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 10,594 shares — an estimated $17.2K sold.

Squarepoint first reported a position in MGX in Q1 2024 and held it in 5 quarters. The position peaked at $279K in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Squarepoint reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 10,594 Metagenomi Therapeutics shares in Q1 2026, an estimated $17.2K.
  • Squarepoint first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 5 quarters.
  • Squarepoint's Metagenomi Therapeutics position peaked at $279K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.